

TABLE OF CONTENTS

THESIS APPROVAL.....	ii
ACKNOWLEDGEMENT.....	iii
STATEMENT OF ORIGINALITY.....	iv
TABLE OF CONTENTS.....	viii
LIST OF TABLES.....	xi
LIST OF FIGURES.....	xii
LIST OF APPENDICES.....	xiii
LIST OF ABBREVIATIONS.....	xiv
Abstrak.....	xv
Abstract.....	xvi
CHAPTER I. INTRODUCTION.....	1
A. Research Background.....	1
B. Research Problem.....	5
C. Research Benefit.....	5
D. Research Objective.....	5
E. Research Authenticity.....	6
CHAPTER II. LITERATURE REVIEW.....	7
A. Theoretical Review.....	7
1. Kidney Transplantation.....	7
2. Mycophenolic Acid.....	9
3. Kidney Allograft Rejection.....	13
4. Structure Annotation of <i>UGT1A9</i> -2152 (C>T).....	15
5. Polymerase Chain Reaction (PCR).....	19
6. HLA Matching.....	23
B. Theoretical Basic.....	23
C. Research Framework.....	27
D. Empirical Statement.....	28
E. Hypothesis.....	28
CHAPTER III. RESEARCH METHOD.....	29
A. Research Design.....	29
B. Place of Research.....	29
F. Population, Subjects, and Materials of Research.....	31
1. Subject criteria.....	31

2.	Sample size calculation.....	32
3.	Regimen after kidney transplantation during maintenance phase.....	32
G.	Research Variable Identification.....	33
1.	Independent variable.....	33
2.	Dependent variable.....	33
3.	Confounding variable.....	33
H.	Operational Definition of Variable.....	34
I.	Research Instruments.....	36
J.	Stages of Research.....	38
1.	Submissions of ethical clearance.....	38
2.	Screening of participants.....	38
3.	Collecting of blood samples.....	39
4.	DNA sample isolation.....	39
5.	DNA Isolate Purity.....	42
6.	Polymerase Chain Reaction Procedure for <i>UGT1A9</i> -2152 (C>T).....	44
K.	Data Analysis.....	45
1.	Genotyping.....	45
2.	Validating Genotyping Result.....	46
3.	Positive Control.....	46
4.	Allele Data Analysis.....	50
CHAPTER IV. RESULT AND DISCUSSION.....		54
A.	Participant Characteristics.....	54
B.	Genotyping of <i>UGT1A9</i> -2152 (C>T).....	60
CHAPTER V. CONCLUSION AND RECOMMENDATION.....		76
A.	Conclusion.....	76
B.	Recommendation.....	76
REFERENCES.....		77
LIST OF APPENDICES.....		85
b.	MGLS (Morisky-Green Levine Scale) Questionnaire form.....	108
c.	List of MGLS Questionnaire Form.....	109
d.	Case Report Form (CRF).....	110
e.	Informed Consent.....	113
f.	Surat izin penelitian laboratorium APSLC.....	114



UNIVERSITAS
GADJAH MADA

The Association of UGT1A9 -2152 (C>T) Gene Polymorphism With Allograft Rejection Among Kidney Transplant Rejection Among Kidney Transplant Recipients Receiving Mycophenolic Acid In Indonesia: A Case Control Study

Aqmarina Tamimi, Prof. Dr. apt. Zullies Ikawati; dr. Yulia Wardhani, Sp.PD-KGH.; Prof. Dr. rer. nat. apt. Adam Herma

Universitas Gadjah Mada, 2025 | Diunduh dari <http://etd.repository.ugm.ac.id/>

RINGKASAN TESIS	115
<i>SUMMARY</i>	122
PUBLICATION MANUSCRIPT	128

LIST OF TABLES

Table 1. Previous study of the <i>UGT1A9</i> – 2152 (C > T) gene polymorphism.....	6
Table 2. Banff categories.....	15
Table 3. Variable and scale measurements of <i>UGT1A9</i> -2152 (C>T).....	34
Table 4. Expected Fragment Lengths for <i>UGT1A9</i> -2152 (C>T) Gene Polymorphism by Genotype.....	44
Table 5. NCBI Primer-BLAST analysis of <i>UGT1A1</i> primers showing specific binding to the target sequence on chromosome 2q37.1.....	47
Table 6. Baseline and clinical characteristics of kidney transplant recipients.....	55
Table 7. Genotypic and allelic frequencies of <i>UGT1A9</i> -2152 (C>T) gene polymorphism.....	66
Table 8. The Hardy-Weinberg equilibrium (HWE) for <i>UGT1A9</i> -2152 (C>T)....	68
Table 9. Genotype Frequencies of <i>UGT1A9</i> -2152 (C>T) Gene Polymorphism Distribution Among Case and Control Groups of Allograft Rejection.....	69
Table 10. Relationship analysis of confounding variables with allograft rejection in Indonesian kidney transplant recipients treated with MPA.....	70

LIST OF FIGURES

Figure 1. Chemical structure of mycophenolate mofetil (MMF).....	11
Figure 2. Mechanism action of mycophenolic acid (MPA).....	13
Figure 3. Mechanisms of T cell priming and activation.....	15
Figure 4. Location of <i>UGT1A9</i> -2152 (C>T) gene in chromosome	17
Figure 5. <i>UGT1A9</i> -2152 (C>T) SNP polymorphism.....	17
Figure 6. RFLP schematic representation of steps involved for mutation.....	22
Figure 7. Research framework.....	27
Figure 8. Restriction Sites of <i>UGT1A9</i> -2152 (C>T).....	49
Figure 9. Punnett square-style of the Hardy-Weinberg Equilibrium.....	52
Figure 10. Visualization of the extracted DNA from whole-blood KTRs.....	62
Figure 11. Primer efficiency validation after amplification (CO01-CO20).....	63
Figure 12. Primer efficiency validation after amplification (CO21-CA15).....	64
Figure 13. The PCR-RFLP analysis was performed on DNA samples.....	65
Figure 14. The PCR-RFLP analysis was performed on DNA samples.....	99

LIST OF APPENDICES

APPENDIX 1. Genotyping analysis results of DNA.....	85
APPENDIX 2. Statistical Analysis of Baseline Characteristics.....	88
APPENDIX 3. Chi-Square test.....	94
APPENDIX 4. PCR-RFLP result was confirmed by GelAnalyzer 23.1.1.....	98
APPENDIX 5. Hardy-Weirberg Equilibrium.....	103
APPENDIX 6. Document related to case control study.....	107

LIST OF ABBREVIATIONS

DNA	=	Deoxyribonucleic acid
PCR	=	Polymerase Chain Reaction
RFLP	=	Restriction Fragment Length Polymorphism
HWE	=	Hardy-Weinberg Equilibrium
KTRs	=	Kidney Transplant Recipients
CC	=	Homozygous Wild type Genotype
CT	=	Heterozygous Genotype
TT	=	Homozygous Mutant Genotype
C	=	Wild type allele (Uncut, normal sequence)
T	=	Variant allele (Polymorphic, contains single nucleotide polymorphism)
SNP	=	Single Nucleotide Polymorphism
MPA	=	Mycophenolic Acid
PK	=	Pharmacokinetics
Cr	=	Serum Creatinine
eGFR	=	Estimated Glomerular Filtration Rate
<i>TruII</i>	=	Restriction Enzyme Used in PCR-RFLP
GelAnalyzer	=	Software for Electrophoresis Image Analysis